Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Down 49.4% in MarchTicker Report • 28 days ago
Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling...
Share to Feed
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...
Tenax Therapeutics GAAP EPS of -$31.04...
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction...
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart...
Tenax Therapeutics (NASDAQ:TENX Get Free Report)s stock had its buy rating reiterated by equities researchers at Roth Mkm in a research report issued to clients and...
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax's territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential...
Tenax Therapeutics, Inc. (NASDAQ:TENX Free Report) Analysts at Zacks Small Cap increased their FY2023 earnings estimates for Tenax Therapeutics in a research note issued on Monday...